Table 1.
Patients’ demographics and characteristics
| Characteristic | Whole population |
No NIP, n (%) | NIP, n (%) | P |
|---|---|---|---|---|
| Total | 310 | 274 (88) | 36 (12) | |
| Median age, years | 61 (23–85) | 60 (23–85) | 67 (45–80) | 0.007 |
| Male | 219 (71) | 197 (72) | 22 (61) | 0.242 |
| Caucasian | 230 (74) | 204 (74) | 26 (72) | 0.744 |
| ECOG PS | 0.49 | |||
| 0 | 34 (11) | 30 (11) | 4 (11) | |
| 1 | 152 (49) | 128 (47) | 24 (67) | |
| 2 | 90 (29) | 86 (31) | 4 (11) | |
| ≥ 3 | 34 (11) | 30 (11) | 4 (11) | |
| Pathology | 0.41 | |||
| Clear-cell | 228 (74) | 198 (72) | 30 (83) | |
| Papillary | 31 (10) | 29 (11) | 2 (6) | |
| Other | 51 (16) | 47 (17) | 4 (11) | |
| Nephrectomy | 228 (74) | 199 (73) | 29 (81) | 0.422 |
| MSKCC prognosis | 0.006 | |||
| Good | 70 (23) | 57 (21) | 13 (36) | |
| Intermediate | 108 (35) | 92 (33) | 16 (44) | |
| Poor | 132 (42) | 125 (46) | 7 (20) | |
| Median Platelets, K | 271 (39–1069) | 281 (39–1069) | 218 (91–540) | 0.007 |
| Median # metastatic sites | 2 (0–7) | 2 (0–7) | 2 (0–6) | 0.851 |
| Prior systemic therapy | 230 (74) | 198 (72) | 32 (89) | 0.041 |
| Median # prior therapy | 1 (0–10) | 1 (0–10) | 1 (0–7) | 0.331 |
| Median time from systemic therapy initiation to mTOR inhibitor, days | 277 (0–6747) | 252 (0–6747) | 440 (0–3430) | 0.048 |
| mTOR inhibitor | <0.001 | |||
| Temsirolimus | 210 (68) | 197 (72) | 13 (36) | |
| Everolimus | 100 (32) | 77 (28) | 23 (64) |